UPDATE: Bank of America Increased Gilead Sciences PT
November 22, 2013 at 15:23 PM EST
On Friday, Bank of America Merrill Lynch analyst Rachel McMinn increased the price objective for Gilead Sciences Inc. (NASDAQ: GILD ) from $96 to $107. McMinn expects an increase in share price, "as investors gain visibility on HCV pricing in late 2013, obtain Phase 3 data in early 2014,
